Q4/2023 12/31/2023 EPS -0.500 ZacksConsensus -0.440 ActVsEst (0.060) - Miss
![Wall Street Horizon](../../../Content/images/providers/WH.png)
Rallybio Corporation (RLYB)
Company Research
Source: Wall Street Horizon
![Wall Street Horizon](../../../Content/images/providers/WH.png)
Impact Snapshot
Event Time:
RLYB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLYB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLYB alerts
High impacting Rallybio Corporation news events
Weekly update
A roundup of the hottest topics
RLYB
News
- Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical TrialBusiness Wire
- Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025Business Wire
RLYB
Earnings
- 8/8/24 - Beat
RLYB
Sec Filings
- 2/12/25 - Form SCHEDULE
- 1/6/25 - Form 4
- 1/6/25 - Form 4
- RLYB's page on the SEC website